Bill
SB 317
Senate Bill 317 allows patients to access psychiatric medications in shortage or discontinued without prior authorization, ensuring timely mental health treatment.
Bill Number: SB 317
Title: Prohibit health insurers from performing prior authorization on psychiatric drugs in shortage or discontinued
Status: Chapter Number Assigned
Introduced: April 08, 2025
Sponsor: Senator Bobby D. Singleton
Subject Areas: Health, Health Care Services, Insurance, Mental Illness or Incapacity
Senate Bill 317 aims to address the challenges faced by patients requiring psychiatric medications that are either in shortage or have been discontinued. The bill seeks to eliminate the prior authorization process imposed by health insurers for these specific medications, thereby facilitating timely access to necessary treatments for individuals experiencing mental health issues.
Prohibition of Prior Authorization: The bill explicitly prohibits health insurers from requiring prior authorization for psychiatric drugs that are currently in shortage or have been discontinued. This change is intended to streamline the process for patients needing these medications, reducing delays in treatment.
Focus on Mental Health: By targeting psychiatric medications, the bill emphasizes the importance of mental health care and aims to ensure that patients can access critical medications without unnecessary bureaucratic hurdles.
Patients: Individuals who rely on psychiatric medications will benefit from the removal of prior authorization requirements, allowing for quicker access to necessary treatments.
Health Insurers: Insurance companies will need to adjust their policies and practices regarding the authorization of psychiatric drugs, particularly those that are in shortage or discontinued.
Healthcare Providers: Mental health professionals will have an easier time prescribing medications without the delays associated with prior authorization, potentially improving patient outcomes.
According to the fiscal notes associated with SB 317, the bill is not expected to have a direct impact on state or local funding. This suggests that the implementation of the bill will not impose additional financial burdens on the state budget.
Senate Bill 317 represents a significant step toward improving access to psychiatric medications for individuals facing mental health challenges. By removing prior authorization requirements for drugs that are in shortage or discontinued, the bill aims to enhance the efficiency of mental health care delivery and ensure that patients receive timely treatment.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
